Equitable Access to High-Cost Pharmaceuticals

With over 25 years of experience in pharmaceutical policy and practice research, Prof Zaheer Babar is a global authority and a prolific author in this field. He comes with a long-standing academic career in pharmacy in New Zealand, and the United Kingdom. He is globally known for his work in policy and practice, including quality use of medicines, and issues related to medicines access and pricing. Prof. Babar has published over 300 papers and is considered the leading researcher in the “pharmacy practice research category”. He has published in high-impact journals such as PLoS Medicine and the Lancet and has acted as a consultant for the WHO, RPS, UNDP, HAI, MSH, FIP, International Union Against Tuberculosis and Lung Disease, World Bank, European Union, and the Pharmaceutical Management Agency of New Zealand. His edited work includes "Economic Evaluation of Pharmacy Services", "Pharmaceutical Prices in the 21st Century", "Pharmaceutical Policies in Countries with Developing Healthcare Systems", "Global Pharmaceutical Policy", "Access to high-cost medicines", "Pharmacy Practice Research Methods", "Pharmacy Practice Research Case Studies" , "Encyclopaedia of Pharmacy Practice and Clinical Pharmacy", and "Encyclopaedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy". Published by Elsevier and Adis/Springer, his work is used in curriculum design, policy development, and referral all around the globe. Professor Babar is the founding Editor-In-Chief of the Journal of Pharmaceutical Policy and Practice [IF = 4.2], a high-impact publication that provides evidence-based insights and recommendations for policymakers, practitioners, and researchers. He can be contacted at: z.babar@hud.ac.uk

"Equitable Access to High-Cost Pharmaceuticals forms an all-inclusive source of knowledge for understanding the issues surrounding access to and cost of new medicines by merging theory with practice, providing a comprehensive outlook on pharmaceutical policy and regulation challenges." --Aris Angelis, The London School of Economics and Political Science

• 1. Access to High Cost Medicines: An Overview2. Health Technology Assessment3. High-Cost Medicines in England4. Managed Entry Agreements and High Cost Medicines (European Perspective)5. Setting a Public Health Agenda to Support Access to High-Cost Medicines6. Human Rights and Intellectual Property for Universal Access to New Essential Medicines7. Access to High Price Medicines in Portugal8. Improving Access to High-Cost Medicines in Low Income Countries in Africa: Creating a Functioning Pharmaceutical System in Uganda9. Equitable Access to Biosimilars: An Overview10. Access to High-Cost Medicines in Europe11. Access to High-Cost Medicines in Australia12. Access to High-Cost Medicines in New Zealand13. Access to High-Cost Medicines in Wales